Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
42291-0726-10 42291-0726 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 3, 2014 In Use
42291-0726-90 42291-0726 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov. 3, 2014 Sept. 19, 2018 In Use
66993-0661-02 66993-0661 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 28, 2015 July 31, 2022 No Longer Used
66993-0661-30 66993-0661 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 28, 2015 July 31, 2022 No Longer Used
66993-0661-88 66993-0661 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 28, 2015 July 31, 2022 No Longer Used
50228-0306-20 50228-0306 Raloxifene hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Oct. 12, 2016 In Use
50228-0306-30 50228-0306 Raloxifene hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Oct. 12, 2016 In Use
70518-2994-00 70518-2994 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 17, 2021 In Use
70518-3046-00 70518-3046 Raloxifene Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral March 11, 2021 In Use
50268-0694-15 50268-0694 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 27, 2018 In Use
00591-2367-01 00591-2367 Raloxifene Hydrochloride Raloxifene 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 18, 2015 In Use
00591-2367-10 00591-2367 Raloxifene Hydrochloride Raloxifene 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 18, 2015 In Use
00591-2367-30 00591-2367 Raloxifene Hydrochloride Raloxifene 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral June 18, 2015 In Use
69189-2367-01 69189-2367 Raloxifene Hydrochloride Raloxifene 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 9, 2016 May 24, 2017 No Longer Used
73491-0627-01 73491-0627 Efbemalenograstim alfa-vuxw RYZNEUTA 20.0 mg/mL Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 23, 2023 In Use
82959-0111-01 82959-0111 imetelstat sodium RYTELO 188.0 mg/1 Chemotherapy Enzyme Inhibitor Telomerase Intravenous June 6, 2024 In Use
82959-0112-01 82959-0112 imetelstat sodium RYTELO 47.0 mg/1 Chemotherapy Enzyme Inhibitor Telomerase Intravenous June 6, 2024 In Use
71332-0005-01 71332-0005 Olutasidenib REZLIDHIA 150.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Dec. 1, 2022 In Use
00002-2980-26 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-2980-60 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-3977-60 00002-3977 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6082-60 00002-6082 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6120-60 00002-6120 Selpercatinib RETEVMO 120.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use

Found 10,000 results in 5 milliseconds — Export these results